Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in DME and RVO (PERMEATE)
NCT02503540Phase 4Completed
- Sponsor
- Justis Ehlers Lab
- Start
- Aug 2015
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), retinal vein occlusion (RVO), sponsored by Justis Ehlers Lab. Started Aug 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT02503540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503540.